Bulletin, Institute

FAST & Fellow Round-up: GigaGen

More success from a CLSI FAST graduate:

  • FAST graduate GigaGen, Inc., announced a $1.37M Phase II grant from the National Cancir Institute’s SBIR program to support discovery and development of oncology drugs from mouse and human B cell repertoires using GigaGen’s novel massively parallel drug discovery technology.  Read the press release here.

FAST provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy.  Some additional recent graduate successes include:

For more information about the FAST program, please contact Steve Karp at